Free Trial

Wan Nurhayati Analyst Performance

Analyst at Cfra

Wan Nurhayati is a stock analyst at Cfra focused in the medical sector, covering 4 publicly traded companies. Over the past year, Wan Nurhayati has issued 2 stock ratings, including and hold recommendations. While full access to Wan Nurhayati's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Wan Nurhayati's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
5 Last 7 Years
Buy Recommendations
25.00% 1 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy25.0%1 ratings
Hold75.0%3 ratings
Sell0.0%0 ratings

Out of 4 total stock ratings issued by Wan Nurhayati at Cfra, the majority (75.0%) have been Hold recommendations, followed by 25.0% Buy.

Exchange Coverage

ExchangePercentageCount
NYSE
100.0% of companies on NYSE
4 companies

Wan Nurhayati, an analyst at Cfra, currently covers 4 companies listed on , with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
3 companies
75.0%
Construction
1 company
25.0%

Wan Nurhayati of Cfra specializes in stock coverage within the Medical sector, with additional focus on Construction companies.

Coverage Industries

IndustryPercentage
LARGE CAP PHARMA
2 companies
50.0%
MED - BIOMED/GENE
1 company
25.0%
BLDG&CONST - MISC
1 company
25.0%

Wan Nurhayati's Ratings History at Cfra

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
GSK PLC Sponsored ADR stock logo
GSK
GSK
10/30/2025Set Price Target$46.81$53.00
Novartis AG stock logo
NVS
Novartis
10/29/2025Set Price Target$123.43$126.00Hold